AI 채팅
Loading data for DERM — first visit, this takes a few seconds.

Journey Medical Corporation

DERM · NasdaqCM · USD

7.23 +0.14 (1.97%)

종가 기준: Sep 11, 2026, 3:59 PM

시가총액
$204.1M

Journey Medical Corporation(DERM) 주가, 분석 및 데이터

내재가치

내재 가치 로딩 중…

애널리스트 전망

주가 전망 →

애널리스트 전망 없음

12개월 목표가 · 애널리스트 n/a명

애널리스트 컨센서스: n/a

간격:1D
캔들과 신호 불러오는 중…

재무 실적

재무 정보 보기 →
매출 (ttm)
$68.18M

불러오는 중...

최근 실적

발표치예상 대비전년 대비
매출$15.96Mn/a+21.48%
EPS-$0.01+$0.01+93.75%

다음 실적 발표

정규장 중입니다.

예상치 · 업그레이드 →

실적 상세 보기 →

지표

매수호가
5.17
순이익 (ttm)
-6.1M
1.10
-0.22
n/a
-120.5
P/B (ttm)
6.23
P/S (ttm)
2.99
실적 발표일
Nov 11, 2026
매도호가
9.24
거래량
167,997
평균 거래량 (20일)
242,456
시가
7.18
전일 종가
7.09
일중 범위
7.06 - 7.41
52주 범위
4.31 - 9.55
배당
n/a
배당락일
n/a

Journey Medical Corporation 소개

기업 정보 보기 →
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Drug Manufacturers - Specialty & Generic · Healthcare

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

섹터 Healthcare
IPO 일자 Nov 12, 2021
직원 수 58
상장 거래소 NasdaqCM
티커 DERM